OBIO Orchestra BioMed Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OBIO

Price (delayed)

$4.41

Market cap

$265.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.85

Enterprise value

$315.35M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 30
Highlights
Orchestra BioMed Holdings's EPS has soared by 54% YoY and by 12% from the previous quarter
Orchestra BioMed Holdings's quick ratio has increased by 18% QoQ
OBIO's net income is up by 15% YoY but it is down by 8% QoQ
Orchestra BioMed Holdings's debt has soared by 110% from the previous quarter
The equity has plunged by 53% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://orchestrabiomed.com
Peers: OM

Key stats

What are the main financial stats of OBIO

OBIO stock price

How has the Orchestra BioMed Holdings stock price performed over time
Intraday
-0.9%
1 week
4.01%
1 month
19.51%
1 year
65.79%
YTD
6.27%
QTD
2.2%

Financial performance

How have Orchestra BioMed Holdings's revenue and profit performed over time
Revenue
$31.98M
Gross profit
$31.82M
Operating income
-$57.99M
Net income
-$59.03M
Gross margin
99.5%
Net margin
-184.6%
OBIO's operating margin has soared by 93% YoY but it is down by 8% QoQ
Orchestra BioMed Holdings's net margin has soared by 92% YoY but it has decreased by 11% from the previous quarter
The operating income has grown by 19% year-on-year but it has declined by 6% since the previous quarter
OBIO's net income is up by 15% YoY but it is down by 8% QoQ

Price vs fundamentals

How does OBIO's price correlate with its fundamentals

Growth

What is Orchestra BioMed Holdings's growth rate over time

Valuation

What is Orchestra BioMed Holdings stock price valuation
P/E
N/A
P/B
13.67
P/S
8.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.86
Orchestra BioMed Holdings's EPS has soared by 54% YoY and by 12% from the previous quarter
The price to book (P/B) is 104% higher than the last 4 quarters average of 6.7
The equity has plunged by 53% from the previous quarter
OBIO's price to sales (P/S) is 93% less than its 5-year quarterly average of 125.4 and 49% less than its last 4 quarters average of 17.2
Orchestra BioMed Holdings's revenue has decreased by 2.3% QoQ

Efficiency

How efficient is Orchestra BioMed Holdings business performance
Orchestra BioMed Holdings's ROS has soared by 93% YoY but it has decreased by 8% from the previous quarter
Orchestra BioMed Holdings's return on invested capital has surged by 71% YoY and by 28% QoQ
The company's return on assets has surged by 50% YoY and by 9% QoQ
OBIO's ROE is up by 48% year-on-year and by 4.5% since the previous quarter

Dividends

What is OBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OBIO.

Financial health

How did Orchestra BioMed Holdings financials performed over time
The company's total assets is 34% higher than its total liabilities
The company's total assets has surged by 170% YoY and by 15% QoQ
OBIO's total liabilities has soared by 103% YoY and by 74% QoQ
Orchestra BioMed Holdings's debt has soared by 110% from the previous quarter
The debt to equity has shrunk by 93% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.